Bismuth Subcitrate Potassium
Eradication regimens for Helicobacter pylori often include a bismuth salt, and bismuth subcitrate potassium serves that role in quadruple therapy. Bismuth compounds deposit a protective layer over ulcerated gastric mucosa and exert direct antimicrobial activity against H. pylori, an effect independent of the antibiotics given alongside them. Because the bismuth component acts by a mechanism unrelated to antibacterial resistance pathways, it retains usefulness where resistance has narrowed the options. Treatment therefore pairs it with antibacterial agents and acid suppression rather than using it alone. The salt is recorded with the formula C12H8BiK5O14 and a formula mass near 780.7 g/mol, and it is an approved agent developed through the final clinical phase.
A bismuth salt used in combination regimens to treat Helicobacter pylori infections of the stomach lining. Bismuth compounds create a protective coating over ulcers and have direct antimicrobial effects against H. pylori. It is typically used alongside antibiotics and acid-reducing medications in eradication therapy.
Peso molecular
780,6500 g/mol
TPSA
287,00 Ų
Áreas terapéuticas
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Estructura 2D
Cite this structure
Embed this structure
SMILES
C(C(=O)[O-])C(CC(=O)[O-])(C(=O)[O-])[O-].C(C(=O)[O-])C(CC(=O)[O-])(C(=O)[O-])[O-].[K+].[K+].[K+].[K+].[K+].[Bi+3]
InChI
InChI=1S/2C6H7O7.Bi.5K/c2*7-3(8)1-6(13,5(11)12)2-4(9)10;;;;;;/h2*1-2H2,(H,7,8)(H,9,10)(H,11,12);;;;;;/q2*-1;+3;5*+1/p-6
Molecular Formula
C12H8BiK5O14
HBD / HBA
- / 14
Enlaces Rotables
4
Átomos Pesados
32
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Preguntas frecuentes
A bismuth salt used in combination regimens to treat Helicobacter pylori infections of the stomach lining. Bismuth compounds create a protective coating over ulcers and have direct antimicrobial effects against H. pylori. It is typically used alongside antibiotics and acid-reducing medications in eradication therapy.
Yes, Bismuth Subcitrate Potassium is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1201186. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 91667825. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-08-20.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="bismuth-subcitrate-potassium"></div>
Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/bismuth-subcitrate-potassium/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>
Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/bismuth-subcitrate-potassium/
Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/bismuth-subcitrate-potassium/)
Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="bismuth-subcitrate-potassium"></drugfyi-drug>